Emerging minimally invasive procedures for focal treatment of organ-confined prostate cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;1:5–29.
   Web of Science ®Google Scholar
• Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995;273:548–52.
   PubMed Web of Science ®Google Scholar
• Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270:948–54.
   PubMed Web of Science ®Google Scholar
• Jacobsen SJ, Katusic SK, Bergstralh EJ, Oesterling JE, Ohrt D, Klee GG, et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA 1995;274:1445–9.
   PubMed Web of Science ®Google Scholar
• Haas GP, Delongchamps N, Brawley OW. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol 2008;15:3866–71
   PubMed Web of Science ®Google Scholar
• Cooperberg M, Broering J, Carroll P. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010;28:1117–23.
   PubMed Web of Science ®Google Scholar
• Ganz PA, Barry JM, Burke W, Col NF, Corso PS, Dodson E, et al. National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. Ann Intern Med 2012;156:591–5.
   PubMed Web of Science ®Google Scholar
• Nomura T, Mimata H. Focal therapy in the management of prostate cancer: an emerging approach for localized prostate cancer. Adv Urol 2012;2012:391437.
   PubMedGoogle Scholar
• Katz AE. The definitive guide to prostate cancer: everything you need to know about conventional and integrative therapies. New York: Rodale, 2011.
   Google Scholar
• Alkhorayef M, Mahmoud MZ, Alzimami KS, Sulieman A, Fagiri MA. High-intensity focused ultrasound (HIFU) in localized prostate cancer treatment. Pol J Radiol2015;80:131–41.
   PubMedGoogle Scholar
• Gelet A, Chaperon JY, Bouvier R, Souchon R, Pangaud C, Abdelrahim AF, et al. Treatment of prostate cancer with transrectal focused ultrasound: early clinical experience. Eur Urol1996;29:174–83.
   PubMed Web of Science ®Google Scholar
• Uchida T, Nakano M, Hongo S, Shoji S, Nagata Y, Satoh T, et al. High intensity focused ultrasound therapy for prostate cancer. Int J Urol 2012;19:187–201.
   PubMed Web of Science ®Google Scholar
• Lindner U, Lawrentschuk N, Trachtenberg J. Focal laser ablation for localized prostate cancer. J Endourol 2010;24:791–7.
   PubMed Web of Science ®Google Scholar
• Huang GT, Wang TH, Sheu JC, Daikuzono N, Sung JL, Wu MZ, Chen DS. Low power laserthermia for the treatment of small hepatocellular carcinoma. Eur J Cancer 1991;27:1622–7.
   PubMed Web of Science ®Google Scholar
• Colin P, Mordon S, Nevoux P, Marqa MF, Ouzzane A, Puech P, et al. Focal laser ablation of prostate cancer: definition, needs and future. Adv Urol 2012;2012:589160.
   PubMedGoogle Scholar
• Ritchie KP, Keller BM, Syed KM, Lepock JR. Hyperthermia (heat shock)-induced protein denaturation in liver, muscle and lens tissue as determined by differential scanning calorimetry. Int J Hyperthermia 1994;10:605–18.
   PubMed Web of Science ®Google Scholar
• Lee T, Mendhiratta N, Sperling D, Lepor H. Focal laser ablation for localized prostate cancer: principles, clinical trials, and our initial experience. Rev Urol 2014;16:55–66.
   PubMedGoogle Scholar
• Miller L, Leor J, Rubinsky B. Cancer cells ablation with irreversible electroporation. Technol Cancer Res Treat 2005;4:699–705.
   PubMed Web of Science ®Google Scholar
• Long G, Bakos G, Shires PK, Gritter L, Crissman JW, Harris JL, Clymer JW. Histological and finite element analysis of cell death due to irreversible electroporation. Technol Cancer Res Treat 2014;13:561–9.
   PubMed Web of Science ®Google Scholar
• Thomson KR, Cheung W, Ellis SJ, Federman D, Kavnoudias H, Loader-Oliver D, et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol 2011;22:611–21.
   PubMed Web of Science ®Google Scholar
• Kasivisvanathan V, Thapar A, Oskrochi Y, Picard J, Leen EL. Irreversible electroporation for focal ablation at the porta hepatis. Cardiovasc Intervent Radiol 2012;35:1531–4.
   PubMed Web of Science ®Google Scholar
• Tsivian M., Polascik T.J. Bilateral focal ablation of prostate tissue using low-energy direct current (LEDC): a preclinical canine study. BJU Int 2013;112:526–30.
   PubMed Web of Science ®Google Scholar
• Valerio M, Stricker PD, Ahmed HU, Dickinson L, Ponsky L, Shnier R, et al. Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer. Prostate cancer Prostatic Dis 2014;17:343–7.
   PubMed Web of Science ®Google Scholar
• Lepor H, Llukani E, Sperling D, Futterer JJ. Complications, recovery, and early functional outcomes and oncologic control following in-bore focal laser ablation of prostate cancer. Eur Urol 2015;68:924–6.
   PubMed Web of Science ®Google Scholar
• Lindner U, Weersink RA, Haider MA, Gertner MR, Davidson SR, Atri M, et al. Image guided photothermal focal therapy for localized prostate cancer: phase 1 trial. J Urol 2009;182:1371–7.
   PubMed Web of Science ®Google Scholar
• Oto A, Sethi I, Karczmar G, McNichols R, Ivancevic MK, Stadler WM, et al. MRI imaging-guided focal laser ablation for prostate cancer: phase 1 trial. Radiology 2013;267:932–40.
   PubMed Web of Science ®Google Scholar
• Ward JF, Jones JS. Focal cryotherapy for localized prostate cancer: a report from the national cryo on-line database (COLD) registry. BJU Int 2011;109:1648–54.
   PubMed Web of Science ®Google Scholar
• Shah TT, Ahmed H, Kanthabalan A, Lau B, Ghei M, Maraj B, Arya M. Focal cryotherapy of localized prostate cancer: a systematic review of the literature. Expert Rev Anticancer Ther 2014;41:1337–47.
   Web of Science ®Google Scholar
• Uchida T, Tomonaga T, Kim H, Nakano M, Shoji S, Nagata Y, Terachi T,. Improved outcomes with advancements in high intensity focused ultrasound for the treatment of localized prostate cancer. J Urol 2015;193:103–10.
   PubMed Web of Science ®Google Scholar
• Warmuth M, Johansson T, Mad P. Systematic review of the efficacy and safety of high intensity focused ultrasound for the primary and salvage treatment of prostate cancer. Eur Urol 2010;58:803–15.
   PubMed Web of Science ®Google Scholar
• Penson D. The pendulum of prostate cancer screening. JAMA 2015;314:2031–3.
   PubMed Web of Science ®Google Scholar
• Jemal A, Fedewa S, Ma J, Siegel R, Lin CC, Brawley O, Ward EM. Prostate cancer incidence and PSA testing patterns in relation to USPSTY screening recommendations. JAMA 2015;314:2054–61.
   PubMed Web of Science ®Google Scholar
• Ahmed H, Hindley R, Dickinson L, Freeman A, Kirkham AP, Sahu M, et al. Focal therapy for localized unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol 2012;13:622–32.
   PubMed Web of Science ®Google Scholar
• Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368–74.
   PubMed Web of Science ®Google Scholar
• Epstein JI. Prognostic significance of tumor volume in radical prostatectomy and needle biopsy specimens. J Urol 2011;186:790–7.
   PubMed Web of Science ®Google Scholar
• Emanu J, Avildsen I, Nelson C. Erectile dysfunction after radical prostatectomy: prevalence, medical treatments, and psychosocial interventions. Curr Opin Support Palliat Care 2016;10:102–7.
   PubMed Web of Science ®Google Scholar
• Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005;95:751–6.
   PubMed Web of Science ®Google Scholar
• Loeb S, Smith ND, Roehl KA, Catalona WJ. Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. Urology 2007; 69:1170–5.
   PubMed Web of Science ®Google Scholar
• Potosky A, Legler J, Albertsen P, Stanford JL, Gilliland FD, Hamilton AS, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the prostate cancer outcomes study. J Natl Cancer Inst 2000;92:1582–92.
   PubMed Web of Science ®Google Scholar
• Salomon L, Droupy S, Yiou R, Soulié M. Functional results and treatment of functional dysfunctions after radical prostatectomy. Prog Urol 2015;25:1028–66.
   PubMed Web of Science ®Google Scholar
• Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250–61.
   PubMed Web of Science ®Google Scholar